Call Start: 08:00 January 1, 0000 9:01 AM ET

Alkermes plc (NASDAQ:ALKS)

Q1 2023 Earnings Conference Call

April 26, 2023 08:00 ET

Company Participants

Sandra Coombs - Senior Vice President of Investor Relations & Corporate Affairs

Richard Pops - Chief Executive Officer

Iain Brown - Chief Financial Officer

Todd Nichols - Chief Commercial Officer

Conference Call Participants

Akash Tiwari - Jeffries

Brandon Folkes - Cantor Fitzgerald

Umer Raffat - Evercore ISI

Chris Shibutani - Goldman Sachs

David Amsellem - Piper Sandler

Paul Matteis - Stifel

Jessica Fye - J.P. Morgan

Jason Gerberry - Bank of America

Marc Goodman - SVB Securities

Douglas Tsao - H.C. Wainwright

Operator

Greetings and welcome to the Alkermes First Quarter 2023 Financial Results Conference Call. My name is Rob and I'll be your operator for today's call. [Operator Instructions] I'll now turn the call over to Sandra Coombs, Senior Vice President of Investor Relations and Corporate Affairs. Sandy, you may begin.

Sandra Coombs

Thank you. Good morning. Welcome to the Alkermes plc conference call to discuss our financial results and business update for the quarter ended March 31, 2023. With me today are Richard Pops, our CEO; Iain Brown, our CFO; and Todd Nichols, our Chief Commercial Officer.

Before we begin, I encourage everyone to go to the Investors section of alkermes.com to find our press release, related financial tables and reconciliations of the GAAP to non-GAAP financial measures that we'll discuss today. We believe the non-GAAP financial results in conjunction with the GAAP results are useful in understanding the ongoing economics of our business. Our discussions during this conference call will include forward-looking statements. Actual results could differ materially from these forward-looking statements. Please see Slide 2 of the accompanying presentation, our press release issued this morning and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information or future results or developments. After our prepared remarks, we'll open the call for Q&A.

And now, I'll turn the call over to Rich.

Richard Pops

Thank you, Sandy. Good morning, everyone. We have a number of important and positive updates to go through today, so I'm going to get right into it. I'm going to start with a brief update on the announcement we made yesterday related to our arbitration with Janssen. I'm then going to hand it to Iain for a review of the financial results for the quarter and then to Todd for an overview of our commercial products. I'll come back then and close with an update on the progress we're making on the separation of the oncology business and our ALKS 2680 Orexin program.